Global Gene Therapy Market Size By Product (Viral Vectors, Non-viral Vectors), By Indication (Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy), By Delivery Method (Ex vivo, In vivo), By Geographic Scope And Forecast

Gene Therapy Market Size And Forecast

Gene Therapy Market size was valued at USD 7.53 Billion in 2024 and is projected to reach USD 50.6 Billion by 2031, growing at a CAGR of 26.88% during the forecast period 2024-2031.

The market’s expansion is due to factors like the development of progressive competition among major firms focusing on the commercialization of their therapies, as well as the expansion of the field of advanced therapeutics and gene delivery technologies. To improve internal expertise and strengthen product pipelines, biotechnology businesses are investing in acquisitions, mergers/collaborations, and expansions. The Global Gene Therapy Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Gene Therapy Market Definition

Gene therapy is a medical method used to treat or prevent disease by addressing the underlying genetic problem. Instead of utilizing drugs or surgery to treat an illness, medical practitioners can now treat it by changing a person’s genetic composition thanks to gene therapy therapies. The original approach to gene therapy, also known as gene transfer or gene addition, was created toIncorporate a new gene into cells to aid in the treatment of a disease. Replace the disease-causing altered copy of the gene with a healthy copy. Later research improved gene therapy techniques. In order to overcome genetic differences, a more contemporary technique known as genome editing (CRISPR-Cas9 is one example) adopts a different strategy.

Genome editing introduces molecular tools to change existing genetic material in cells as opposed to adding new genetic material. Gene therapy is being used to treat a small number of illnesses, such as spinal muscular atrophy and the eye condition Leber congenital amaurosis. Many more gene therapies are being researched to make sure they will be effective and safe. Soon, doctors hope to use the promising method of genome editing to treat human ailments. Gene therapy products come in a variety of forms, includingPlasmid DNAIt is possible to genetically modify circular DNA molecules to deliver therapeutic genes into human cells.

viral carriers Since viruses naturally have the ability to insert genetic material into cells, certain gene therapy products are created from them. Once viruses have been edited to lessen their ability to spread infectious disease, these modified viruses can be used as vectors (vehicles) to deliver therapeutic genes into human cells. Bacterial vectors can be altered to stop them from spreading infectious diseases, and they can then be utilized as vehicles to deliver therapeutic genes into human tissues. Technology for modifying human genesGene editing aims to remove undesirable genes or fix mutated genes. To develop patient-derived cellular gene therapy products, cells are taken from the patient, genetically modified (usually using a viral vector), and then given back to the patient.

Global Gene Therapy Market Overview

Market expansion has been significantly hindered by the COVID-19 outbreak. Due to COVID-19, which has historically posed substantial issues in the supply of materials, production, and logistics operations, this industry has been severely disrupted. For instance, when a partner contract manufacturing company was forced to shut down, a gene therapy company that had long delivery dates for some components later found that it was short on clinical trial supplies. During the forecast period, a strong gene therapy pipeline is anticipated to drive market expansion. Gene therapy is being developed so that clinics can offer it.

Numerous colleges and institutes are seen to have a wide range of products in the works, which is anticipated to increase revenue-generating in the near future. Following the FDA’s approval of the first gene treatment, the number of clinical trials for gene therapy significantly increased. Around 1,986 gene therapy products, including CAR T-cell treatments and other genetically modified cell therapies, are being developed, according to the American Society of Gene & Cell Therapy (ASGCT). Additionally, during the projection period, the gene therapy market will benefit from improved regulatory backing. Numerous international regulatory organizations have enhanced the techniques they use to promote therapies. The FDA’s endorsement of CAR-T technology is one example.

Especially in phase II and III research, regulators are allowing flexibility within the traditional hierarchy of how clinical trials are conducted. A further prediction made by the FDA was that by 2025, 10 to 20 innovative cell and gene therapies would be authorized yearly. The industry is also expected to provide market participants tremendous development potential as a result of increasing funding and investments. Numerous biopharma companies are making investments in the region to launch cutting-edge drugs. For instance, Ori Biotech launched a cutting-edge platform for studying cell and gene therapies in January 2022 after raising more than USD 100.0 million in Series B funding. With the help of this cash, pre-commercialization and market launch could proceed rapidly.

Global Gene Therapy Market Segmentation Analysis

The Global Gene Therapy Market is Segmented on the basis of Product, Indication, Delivery Method  And Geography.

Gene Therapy Market, By Product

• Viral Vectors
• Non-viral Vectors

Based on Product, the market is segmented into Viral Vectors, Non-viral Vectors. Viral Vector is the largest global Gene Therapy  Market during the forecast period. Due to the simplicity of DNA insertion and separation, retroviruses were the most often employed viruses in gene therapy applications. The two copies of single-stranded RNA that are produced by retroviruses can be changed into double-stranded DNA, which can then be incorporated into the chromosomes of the host cell. Many active clinical studies are primarily focused on the use of retroviruses.

Gene Therapy Market, By Indication

• Neurological Diseases
• Cancer
• Hepatological Diseases
• Duchenne Muscular Dystrophy
• Other Indications

Based on Indication, the market is bifurcated into Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy,  and Other Indications. Cancer Segment are the fastest global Gene Therapy  Market during the forecast period. The oncological diseases market is anticipated to expand at the quickest CAGR during the projected period as a result of the approval of an increasing number of gene therapies for cancer treatment and the rising frequency of hematologic cancers. The sector for neurological illnesses is anticipated to be the most opportunistic during the projected period, on the other hand. With the development of targeted gene therapy, it is now possible to treat serious neurological disorders utilizing a range of methods, including exogenous gene expression and endogenous gene repression.

Gene Therapy Market, By Delivery Method

• Ex vivo
• In vivo

Based on Delivery Method, the market is segmented into Ex vivo, In vivo. The in vivo therapy market share was the greatest. Future market expansion is anticipated to be fueled by a rise in in vivo gene therapy use across the globe. Compared to ex vivo gene therapy, where cells are altered outside the body and subsequently reintroduced to the patient, in vivo gene therapy offers the advantage of being a potentially more direct and systemic method. In vivo gene therapy is not without its difficulties, though, including the need for effective and focused genetic material delivery, a reduction in immune reactions, and long-term expression of the therapeutic genes.

 Gene Therapy Market, By Geographic Scope

• North America
• Europ
• Asia Pacific
• Rest of the World

Based on regional analysis, the Global Gene Therapy  Market is classified into North America, Europe, Asia Pacific,  Middle East and Africa and Latin America. Throughout the anticipated period The North America is expected to hold the largest market share of the Gene Therapy  over the forecast period. According to the number of approvals and the amount of money made during the projected period, this area is anticipated to become the largest routine manufacturer of gene therapy. It is projected that the market will continue to grow as more large and small businesses make R&D investments in the creation of medications for optimum therapy. The market is also being driven by the government’s growing investment levels and the rising incidence of certain ailments. The Spinal Muscular Atrophy Foundation estimates that between 10,000 and 25,000 children and adults in the United States will have spinal muscular atrophy in 2020, making it one of the more prevalent uncommon diseases.

Key Players

The “Global Gene Therapy Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as Pfizer, Novartis AG, Biogen, Gilead Sciences, Inc., MolMed S.p.A., Spark Therapeutics, Inc., Orchard Therapeutics plc., SIBIONO, Bluebird bio, Inc., Shanghai Sunway Biotech Co. Ltd., and Human Stem Cells Institute.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Development

• In April 2022, In the Phase 3 trials of experimental gene therapy for patients with Duchenne muscular dystrophy, Pfizer, Inc. announced its intention to open its first U.S. location. The global Phase 3 CIFFREO study was restarted after receiving regulatory agency approval from Canada, Taiwan, the UK, Spain, and Belgium.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Gene Therapy  Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in Global Gene Therapy  Market gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Ana